Overal Survival, Non-small Cell Lung Cancer
Conditions
Brief summary
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective clinical trials. The researches aim to analysis whether bone metastasis could affect the survival of NSCLC patients who were effective in Gefitinib treatment over 6 months.
Detailed description
The epidermal growth factor receptors (EGFRs) have inhibitory effects on cell apoptosis, cell growth, angiogenesis and metastasis of tumor cell. The advent of EGFR-TKI significantly improved the clinical efficacy and safety of non-small cell lung cancer (NSCLC) treatment. Compelling study also demonstrate Gefitinib may be effective in the treatment of bone metastases. For NSCLC patients who were effective in EGFR-TKI treatment, whether bone metastasis would shorten the survival time of the patients or reduce the quality of life of patients is worth studying. The researches aim to analysis whether bone metastasis could affect the survival of NSCLC patients who were effective in Gefitinib treatment over 6 months.
Interventions
DRUGGefitinib
Daily oral administration of 250 mg Gefitinib
Sponsors
Qilu Hospital of Shandong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. histological and (or) cytological diagnosed NSCLC patients. 2. patient was effective in Gefitinib treatment more than 6 months. 3. whether patient received chemotherapy and other treatment is not restricted. 4. whether patient was detected for EGFR gene mutation was not restricted.
Exclusion criteria
1. patient with small cell lung cancer. 2. patient without cytology or histopathology diagnosis results. 3. patient with bone metastases cannot rule out other reasons such as inflammation or trauma. 4. patient with poor treatment compliance. 5. patient with incomplete data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overal survival of patients | 5 years | The 5-year survival of NSCLC patients with or without bone metastasis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival of patients with both bone metastasis and brain metastasis | 3 years | Survival of patients with both bone metastasis and brain metastasis |
Outcome results
None listed